title: [The evaluation of strengthened psychological and behavioral intervention in smoking cessation clinics].
abstract: OBJECTIVE
  To evaluate the effect of psychological and behavioral intervention combined with varenicline smoking cessation clinics and to analyze predictors of successful quitting.
  
  
  METHODS
  Subjects were collected from quitters who went to receive consultation and intervention in "smoking and related diseases" clinic at Zhongshan Hospital, Fudan University from March 2009 to September 2010. Eligible subjects were screened and divided into strengthen follow-up group and control group. The 4 weeks continuous abstinence rate from week 9 through week 12 were observed logistic regression model and used to analyze the predictors of successful quitting.
  
  
  RESULTS
  Subjects who are addicted to nicotine received strengthening psychological and behavioral intervention combined with varenicline in smoking cessation clinics. The total continuous cessation rate during the 9(th) - 12(th) week was 52.3%, with 60.9% (28/46) and 46.2% (30/65) of strengthen follow-up group and control group respectively. The most frequent adverse effects were nausea 39.6% (44/111), insomnia and abnormal dreams 17.1% (19/111). Adverse effects were tolerable and withdraw symptoms were few. Preparation and medication time can be used as predictors of successful quitting.
  
  
  CONCLUSIONS
  The quit rate of varenicline therapy combining with strengthen intervention is high and strengthening psychological and behavioral intervention could increase the success rate more obviously, which is a good choice for cessation therapy in smoking cessation clinics. Better preparation and regular adequate treatment can improve quit rate.
authors.affiliation: Department of Respiratory, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Wen-ting
authors.initials: WT
authors.lastname: Jin
authors.forename: Xiao-dan
authors.initials: XD
authors.lastname: Wang
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.forename: Chun-xue
authors.initials: CX
authors.lastname: Bai
authors.forename: Jue
authors.initials: J
authors.lastname: Pan
mesh_terms: D000328:Adult; D001552:Benzazepines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011613:Psychotherapy; D011810:Quinoxalines / Q000627:therapeutic use; D012907:Smoking / Q000628:therapy*; D016540:Smoking Cessation / Q000379:methods*; D016896:Treatment Outcome; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D011810:Quinoxalines; D000068580:Varenicline